C32.0 Description: Malignant neoplasm of glottis Inclusion Term:
Malignant neoplasm of intrinsic larynx
Malignant neoplasm of laryngeal commissure (anterior)(posterior)
Malignant neoplasm of vocal cord (true) NOS
↓
C32 Description: Malignant neoplasm of larynx Use Additional Code:
code to identify:
alcohol abuse and dependence (F10.-)
exposure to environmental tobacco smoke (Z77.22)
exposure to tobacco smoke in the perinatal period (P96.81)
history of tobacco dependence (Z87.891)
occupational exposure to environmental tobacco smoke (Z57.31)
tobacco dependence (F17.-)
tobacco use (Z72.0)
↓
C30-C39 Description: Malignant neoplasms of respiratory and intrathoracic organs (C30-C39) Exclude1:
mesothelioma (C45.-)
Include:
malignant neoplasm of middle ear
↓
C00-D49 Description: Neoplasms Notes:
Functional activity
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
Morphology [Histology]
Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
Primary malignant neoplasms overlapping site boundaries
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Malignant neoplasm of ectopic tissue
Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).